About this Journal Submit a Manuscript Table of Contents 
Neural Plasticity
Volume 2012 (2012), Article ID 832757, 12 pages
doi:10.1155/2012/832757
Review Article

Effects of Antipsychotics on Dentate Gyrus Stem Cell Proliferation and Survival in Animal Models: A Critical Update

Gerburg Keilhoff,1 Paolo Fusar-Poli,2 and Axel Becker3

1Institute of Biochemistry and Cell Biology, University of Magdeburg, Leipziger Straße 44, 39120 Magdeburg, Germany
2Institute of Psychiatry, King's College London, 5th Floor, Main Building, P.O. Box 63, De Crespigny Park, London SE5 8AF, UK
3Institute of Pharmacology and Toxicology, University of Magdeburg, Leipziger Straße 44, 39120 Magdeburg, Germany

Received 12 June 2012; Revised 19 September 2012; Accepted 20 September 2012

Academic Editor: Chitra D. Mandyam

Copyright © 2012 Gerburg Keilhoff et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. A. Bayer, P. Falkai, and W. Maier, “Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the “two hit hypothesis“,” Journal of Psychiatric Research, vol. 33, no. 6, pp. 543–548, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. T. M. Maynard, L. Sikich, J. A. Lieberman, and A. S. LaMantia, “Neural development, cell-cell signaling, and the “two-hit” hypothesis of schizophrenia,” Schizophrenia Bulletin, vol. 27, no. 3, pp. 457–476, 2001. View at Scopus
  3. C. Pantelis, M. Yücel, S. J. Wood, P. D. McGorry, and D. Velakoulis, “Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences,” Australian and New Zealand Journal of Psychiatry, vol. 37, no. 4, pp. 399–406, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. J. L. Rapoport, A. M. Addington, S. Frangou, and M. R. C. Psych, “The neurodevelopmental model of schizophrenia: update 2005,” Molecular Psychiatry, vol. 10, no. 5, pp. 434–449, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Fusar-Poli, S. Borgwardt, A. Bechdolf, et al., “The psychosis high risk state: a comprehensive state of the art review,” Archives of General Psychiatry. In press.
  6. P. Fusar-Poli, I. Bonoldi, and A. R. Yung, “Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk,” Archives of General Psychiatry, vol. 69, no. 3, pp. 220–229, 2012.
  7. P. Fusar-Poli, A. Bechdolf, M. Taylor, et al., “At risk for schizophrenic or affective psychosis? A meta-analysis of ICD/DSM diagnostic outcomes in individuals at high clinical risk,” Schizophrenia Bulletin. In press. View at Publisher · View at Google Scholar
  8. P. Fusar-Poli, G. Deste, R. Smieskova, et al., “Cognitive functioning in prodromal psychosis: a meta-analysis,” Archives of General Psychiatry, vol. 69, no. 6, pp. 562–571, 2012.
  9. P. Fusar-Poli, S. Borgwardt, A. Crescini et al., “Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis,” Neuroscience and Biobehavioral Reviews, vol. 35, no. 5, pp. 1175–1185, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Fusar-Poli, J. Radua, P. McGuire, and S. Borgwardt, “Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies,” Schizophrenia Bulletin. In press. View at Publisher · View at Google Scholar
  11. R. Smieskova, P. Fusar-Poli, P. Allen et al., “Neuroimaging predictors of transition to psychosis—a systematic review and meta-analysis,” Neuroscience and Biobehavioral Reviews, vol. 34, no. 8, pp. 1207–1222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Fusar-Poli, O. D. Howes, P. Allen et al., “Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study,” Archives of General Psychiatry, vol. 67, no. 7, pp. 683–691, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Fusar-Poli, O. D. Howes, P. Allen et al., “Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis,” Molecular Psychiatry, vol. 16, no. 1, pp. 67–75, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Fusar-Poli, J. Perez, M. Broome et al., “Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis,” Neuroscience and Biobehavioral Reviews, vol. 31, no. 4, pp. 465–484, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. N. A. Crossley, A. Mechelli, P. Fusar-Poli et al., “Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis,” Human Brain Mapping, vol. 30, no. 12, pp. 4129–4137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Fusar-Poli and A. Meyer-Lindenberg, “Striatal presynaptic dopamine in schizophrenia—part II: meta-analysis of [18F]/[11C] DOPA PET studies,” Schizophrenia Bulletin. In press. View at Publisher · View at Google Scholar
  17. P. Fusar-Poli, J. Stone, M. Broome, I. Valli, A. Mechelli, and M. McLean, “Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis,” Archives of General Psychiatry, vol. 68, no. 9, pp. 881–890, 2011.
  18. O. D. Howes, A. J. Montgomery, M. C. Asselin et al., “Elevated striatal dopamine function linked to prodromal signs of schizophenia,” Archives of General Psychiatry, vol. 66, no. 1, pp. 13–20, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. P. McGuire, O. D. Howes, J. Stone, and P. Fusar-Poli, “Functional neuroimaging in schizophrenia: diagnosis and drug discovery,” Trends in Pharmacological Sciences, vol. 29, no. 2, pp. 91–98, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Fusar-Poli and A. R. Yung, “Should attenuated psychosis syndrome be included in the DSM5? The debate,” The Lancet, vol. 379, no. 9816, pp. 591–592, 2012.
  21. I. Arnold and F. M. Watt, “c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny,” Current Biology, vol. 11, no. 8, pp. 558–568, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Reif, S. Fritzen, M. Finger et al., “Neural stem cell proliferation is decreased in schizophrenia, but not in depression,” Molecular Psychiatry, vol. 11, no. 5, pp. 514–522, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. T. E. Kippin, S. Kapur, and D. Van Der Kooy, “Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs,” Journal of Neuroscience, vol. 25, no. 24, pp. 5815–5823, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. C. G. Wakade, S. P. Mahadik, J. L. Waller, and F. C. Chiu, “Atypical neuroleptics stimulate neurogenesis in adult rat brain,” Journal of Neuroscience Research, vol. 69, no. 1, pp. 72–79, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. H. D. Wang, F. D. Dunnavant, T. Jarman, and A. Y. Deutch, “Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat,” Neuropsychopharmacology, vol. 29, no. 7, pp. 1230–1238, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Kodama, T. Fujioka, and R. S. Duman, “Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat,” Biological Psychiatry, vol. 56, no. 8, pp. 570–580, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. N. D. Halim, C. S. Weickert, B. W. McClintock, D. R. Weinberger, and B. K. Lipska, “Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus,” Neuropsychopharmacology, vol. 29, no. 6, pp. 1063–1069, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Piontkewitz, H. G. Bernstein, H. Dobrowolny, B. Bogerts, I. Weiner, and G. Keilhoff, “Effects of risperidone treatment in adolescence on hippocampal neurogenesis, parvalbumin expression, and vascularization following prenatal immune activation in rats,” Brain, Behavior, and Immunity, vol. 26, no. 2, pp. 353–363, 2012.
  29. G. Keilhoff, G. Grecksch, and A. Becker, “Haloperidol normalized prenatal vitamin D depletion-induced reduction of hippocampal cell proliferation in adult rats,” Neuroscience Letters, vol. 476, no. 2, pp. 94–98, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Keilhoff, G. Grecksch, H. G. Bernstein, T. Roskoden, and A. Becker, “Risperidone and haloperidol promote survival of stem cells in the rat hippocampus,” European Archives of Psychiatry and Clinical Neuroscience, vol. 260, no. 2, pp. 151–162, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Castagné, P. C. Moser, and R. D. Porsolt, “Preclinical behavioral models for predicting antipsychotic activity,” Advances in Pharmacology, vol. 57, pp. 381–418, 2009. View at Scopus
  32. C. A. Jones, D. J. Watson, and K. C. Fone, “Animal models of schizophrenia,” British Journal of Pharmacology, vol. 164, no. 4, pp. 1162–1194, 2011.
  33. L. Lu, T. Mamiya, T. Koseki, A. Mouri, and T. Nabeshima, “Genetic animal models of schizophrenia related with the hypothesis of abnormal neurodevelopment,” Biological & Pharmaceutical Bulletin, vol. 34, no. 9, pp. 1358–1363, 2011.
  34. H. Moore, “The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy,” Schizophrenia Bulletin, vol. 36, no. 6, pp. 1066–1072, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. J. C. Neill, S. Barnes, S. Cook et al., “Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism,” Pharmacology and Therapeutics, vol. 128, no. 3, pp. 419–432, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. S. B. Powell, “Models of neurodevelopmental abnormalities in schizophrenia,” Current Topics in Behavioral Neurosciences, vol. 4, pp. 435–481, 2010.
  37. S. Tordjman, D. Drapier, O. Bonnot et al., “Animal models relevant to schizophrenia and autism: validity and limitations,” Behavior Genetics, vol. 37, no. 1, pp. 61–78, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. J. W. Young, X. Zhou, and M. A. Geyer, “Animal models of schizophrenia,” Current Topics in Behavioral Neurosciences, no. 4, pp. 391–433, 2010.
  39. P. C. Ashe, M. D. Berry, and A. A. Boulton, “Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 25, no. 4, pp. 691–707, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Cannon and R. M. Murray, “Neonatal origins of schizophrenia,” Archives of Disease in Childhood, vol. 78, no. 1, pp. 1–3, 1998.
  41. D. R. Weinberger, “From neuropathology to neurodevelopment,” Lancet, vol. 346, no. 8974, pp. 552–557, 1995. View at Scopus
  42. P. Falkai and B. Bogerts, “Cell loss in the hippocampus of schizophrenics,” European Archives of Psychiatry and Neurological Sciences, vol. 236, no. 3, pp. 154–161, 1986. View at Scopus
  43. S. Heckers and C. Konradi, “Hippocampal neurons in schizophrenia,” Journal of Neural Transmission, vol. 109, no. 5-6, pp. 891–905, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Heckers, “The hippocampus in schizophrenia,” American Journal of Psychiatry, vol. 161, no. 11, pp. 2138–2139, 2004. View at Scopus
  45. N. C. Allen, S. Bagade, M. B. McQueen et al., “Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database,” Nature Genetics, vol. 40, no. 7, pp. 827–834, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Desbonnet, J. L. Waddington, and C. M. P. O'Tuathaigh, “Mutant models for genes associated with schizophrenia,” Biochemical Society Transactions, vol. 37, no. 1, pp. 308–312, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. P. J. Harrison, D. Pritchett, K. Stumpenhorst, J. F. Betts, W. Nissen, and J. Schweimer, “Genetic mouse models relevant to schizophrenia: taking stock and looking forward,” Neuropharmacology, vol. 62, no. 3, pp. 1164–1167, 2012.
  48. A. Guidotti, C. Pesold, and E. Costa, “New neurochemical markers for psychosis: a working hypothesis of their operation,” Neurochemical Research, vol. 25, no. 9-10, pp. 1207–1218, 2000. View at Scopus
  49. H. Stefansson, E. Sigurdsson, V. Steinthorsdottir et al., “Neuregulin 1 and susceptibility to schizophrenia,” American Journal of Human Genetics, vol. 71, no. 4, pp. 877–892, 2002. View at Scopus
  50. C. S. Barros, B. Calabrese, P. Chamero et al., “Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 11, pp. 4507–4512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Niwa, A. Kamiya, R. Murai et al., “Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits,” Neuron, vol. 65, no. 4, pp. 480–489, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Kellendonk, E. H. Simpson, H. J. Polan et al., “Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning,” Neuron, vol. 49, no. 4, pp. 603–615, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. I. H. Deakin, W. Nissen, A. J. Law, T. Lane, R. Kanso, and M. H. Schwab, “Transgenic overexpression of the type I isoform of neuregulin 1 affects working memory and hippocampal oscillations but not long-term potentiation,” Cerebral Cortex, vol. 22, no. 7, pp. 1520–1529, 2012.
  54. A. Egerton and J. M. Stone, “The glutamate hypothesis of schizophrenia: neuroimaging and drug development,” Current Pharmaceutical Biotechnology, vol. 13, no. 8, pp. 1500–1512, 2012.
  55. G. E. Duncan, S. S. Moy, A. Perez et al., “Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function,” Behavioural Brain Research, vol. 153, no. 2, pp. 507–519, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. R. L. Fradley, G. F. O'Meara, R. J. Newman, A. Andrieux, D. Job, and D. S. Reynolds, “STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating,” Behavioural Brain Research, vol. 163, no. 2, pp. 257–264, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. T. B. Halene, R. S. Ehrlichman, Y. Liang et al., “Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia,” Genes, Brain and Behavior, vol. 8, no. 7, pp. 661–675, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. A. J. Ramsey, “NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia,” Progress in Brain Research, vol. 179, pp. 51–58, 2009. View at Scopus
  59. R. R. Gainetdinov, “Dopamine transporter mutant mice in experimental neuropharmacology,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 377, no. 4–6, pp. 301–313, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. C. M. O'Tuathaigh, L. Desbonnet, P. M. Moran, B. P. Kirby, and J. L. Waddington, “Molecular genetic models related to schizophrenia and psychotic illness: heuristics and challenges,” Current Topics in Behavioral Neurosciences, vol. 7, pp. 87–119, 2011.
  61. C. M. P. O'Tuathaigh, B. P. Kirby, P. M. Moran, and J. L. Waddington, “Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia,” Schizophrenia Bulletin, vol. 36, no. 2, pp. 271–288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Babovic, C. M. O'Tuathaigh, A. M. O'Connor et al., “Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase,” Neuroscience, vol. 155, no. 4, pp. 1021–1029, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. J. A. Gogos, M. Morgan, V. Luine et al., “Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 17, pp. 9991–9996, 1998. View at Publisher · View at Google Scholar · View at Scopus
  64. U. Meyer, I. Knuesel, M. Nyffeler, and J. Feldon, “Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis,” Psychopharmacology, vol. 208, no. 4, pp. 531–543, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. C. E. McKibben, T. A. Jenkins, H. N. Adams, M. K. Harte, and G. P. Reynolds, “Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat,” Behavioural Brain Research, vol. 208, no. 1, pp. 132–136, 2010. View at Scopus
  66. K. Maeda, H. Sugino, T. Hirose et al., “Clozapine prevents a decrease in neurogenesis in mice repeatedly treated with phencyclidine,” Journal of Pharmacological Sciences, vol. 103, no. 3, pp. 299–308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Negrete-Díaz, E. Baltazar-Gaytán, M. Bringas et al., “Neonatal ventral hippocampus lesion induces increase in no levels which is attenuated by subchronic haloperidol treatment,” Synapse, vol. 64, no. 12, pp. 941–947, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. F. H. Gage, “Mammalian neural stem cells,” Science, vol. 287, no. 5457, pp. 1433–1438, 2000. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Alvarez-Buylla and J. M. García-Verdugo, “Neurogenesis in adult subventricular zone,” Journal of Neuroscience, vol. 22, no. 3, pp. 629–634, 2002. View at Scopus
  70. D. K. Ma, M. C. Marchetto, J. U. Guo, G. L. Ming, F. H. Gage, and H. Song, “Epigenetic choreographers of neurogenesis in the adult mammalian brain,” Nature Neuroscience, vol. 13, no. 11, pp. 1338–1344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. B. Artegiani and F. Calegari, “Age-related cognitive decline: can neural stem cells help us?” Aging, vol. 4, no. 3, pp. 176–186, 2012.
  72. A. Marin-Burgin and A. F. Schinder, “Requirement of adult-born neurons for hippocampus-dependent learning,” Behavioural Brain Research, vol. 227, no. 2, pp. 391–399, 2012.
  73. J. S. Snyder, A. Soumier, M. Brewer, J. Pickel, and H. A. Cameron, “Adult hippocampal neurogenesis buffers stress responses and depressive behaviour,” Nature, vol. 476, no. 7361, pp. 458–461, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. A. J. Eisch, H. A. Cameron, J. M. Encinas, L. A. Meltzer, G. L. Ming, and L. S. Overstreet-Wadiche, “Adult neurogenesis, mental health, and mental illness: hope or hype?” Journal of Neuroscience, vol. 28, no. 46, pp. 11785–11791, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. A. Foret, R. Quertainmont, O. Botman et al., “Stem cells in the adult rat spinal cord: plasticity after injury and treadmill training exercise,” Journal of Neurochemistry, vol. 112, no. 3, pp. 762–772, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. Xiong, A. Mahmood, and M. Chopp, “Angiogenesis, neurogenesis and brain recovery of function following injury,” Current Opinion in Investigational Drugs, vol. 11, no. 3, pp. 298–308, 2010. View at Scopus
  77. A. Erlandsson, C. H. Lin, F. Yu, and C. M. Morshead, “Immunosuppression promotes endogenous neural stem and progenitor cell migration and tissue regeneration after ischemic injury,” Experimental Neurology, vol. 230, no. 1, pp. 48–57, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. C. Zhao, M. Zawadzka, A. J. A. Roulois, C. C. Bruce, and R. J. M. Franklin, “Promoting remyelination in multiple sclerosis by endogenous adult neural stem/precursor cells: defining cellular targets,” Journal of the Neurological Sciences, vol. 265, no. 1-2, pp. 12–16, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. J. P. Hugnot and R. Franzen, “The spinal cord ependymal region: a stem cell niche in the caudal central nervous system,” Frontiers in Bioscience, vol. 16, no. 3, pp. 1044–1059, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Geraerts, O. Krylyshkina, Z. Debyser, and V. Baekelandt, “Concise review: therapeutic strategies for Parkinson disease based on the modulation of adult neurogenesis,” Stem Cells, vol. 25, no. 2, pp. 263–270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Rioux and S. E. Arnold, “The expression of retinoic acid receptor alpha is increased in the granule cells of the dentate gyrus in schizophrenia,” Psychiatry Research, vol. 133, no. 1, pp. 13–21, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. M. E. Atz, B. Rollins, and M. P. Vawter, “NCAM1 association study of bipolar disorder and schizophrenia: polymorphisms and alternatively spliced isoforms lead to similarities and differences,” Psychiatric Genetics, vol. 17, no. 2, pp. 55–67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. E. Gascon, L. Vutskits, and J. Z. Kiss, “The role of PSA-NCAM in adult neurogenesis,” Advances in Experimental Medicine and Biology, vol. 663, pp. 127–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. H. G. Bernstein, J. Steiner, and B. Bogerts, “Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy,” Expert Review of Neurotherapeutics, vol. 9, no. 7, pp. 1059–1071, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. R. D. Fields, “White matter in learning, cognition and psychiatric disorders,” Trends in Neurosciences, vol. 31, no. 7, pp. 361–370, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. N. Takahashi, T. Sakurai, K. L. Davis, and J. D. Buxbaum, “Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia,” Progress in Neurobiology, vol. 93, no. 1, pp. 13–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Rothermundt, J. N. Ahn, and S. Jorgens, “S100B in schizophrenia: an update,” General Physiology and Biophysics, vol. 28, pp. F76–F81, 2009.
  88. S. D. Bilbo and J. M. Schwarz, “Early-life programming of later-life brain and behavior: a critical role for the immune system,” Frontiers in Behavioral Neuroscience, vol. 3, article 14, 2009.
  89. G. J. Harry and A. D. Kraft, “Microglia in the developing brain: a potential target with lifetime effects,” Neurotoxicology, vol. 33, no. 2, pp. 191–206, 2012.
  90. H. Neumann, M. R. Kotter, and R. J. M. Franklin, “Debris clearance by microglia: an essential link between degeneration and regeneration,” Brain, vol. 132, no. 2, pp. 288–295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Olah, S. Amor, N. Brouwer, J. Vinet, B. Eggen, and K. Biber, “Identification of a microglia phenotype supportive of remyelination,” Glia, vol. 60, no. 2, pp. 306–321, 2012.
  92. M. E. Tremblay, B. Stevens, A. Sierra, H. Wake, and A. Bessis, “Nimmerjahn A. The role of microglia in the healthy brain,” Journal of Neuroscience, vol. 31, no. 45, pp. 16064–16069, 2011.
  93. N. A. Crossley, M. Constante, P. McGuire, and P. Power, “Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis,” British Journal of Psychiatry, vol. 196, no. 6, pp. 434–439, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. J. Horacek, V. Bubenikova-Valesova, M. Kopecek et al., “Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia,” CNS Drugs, vol. 20, no. 5, pp. 389–409, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. F. Angelucci, A. A. Mathé, and L. Aloe, “Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia,” Progress in Brain Research, vol. 146, pp. 151–165, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. E. Prommer, “Olanzapine: palliative medicine update,” American Journal of Hospice Palliative Care. In press.
  97. R. G. Steen, C. Mull, R. McClure, R. M. Hamer, and J. A. Lieberman, “Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies,” British Journal of Psychiatry, vol. 188, pp. 510–518, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. L. D. Selemon, M. S. Lidow, and P. S. Goldman-Rakic, “Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure,” Biological Psychiatry, vol. 46, no. 2, pp. 161–172, 1999. View at Publisher · View at Google Scholar · View at Scopus
  99. M. A. Riva, R. Molteni, F. Tascedda, A. Massironi, and G. Racagni, “Selective modulation of fibroblast growth factor-2 expression in the rat brain by the atypical antipsychotic clozapine,” Neuropharmacology, vol. 38, no. 7, pp. 1075–1082, 1999. View at Publisher · View at Google Scholar · View at Scopus
  100. F. Fumagalli, R. Molteni, F. Bedogni et al., “Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801,” NeuroReport, vol. 15, no. 13, pp. 2109–2112, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. F. Angelucci, S. Brenè, and A. A. Mathé, “BDNF in schizophrenia, depression and corresponding animal models,” Molecular Psychiatry, vol. 10, no. 4, pp. 345–352, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. P. F. Buckley, A. Pillai, D. Evans, E. Stirewalt, and S. Mahadik, “Brain derived neurotropic factor in first-episode psychosis,” Schizophrenia Research, vol. 91, no. 1–3, pp. 1–5, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. P. F. Buckley, A. Pillai, and K. R. Howell, “Brain-derived neurotrophic factor: findings in schizophrenia,” Current Opinion in Psychiatry, vol. 24, no. 2, pp. 122–127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. M. J. Green, S. L. Matheson, A. Shepherd, C. S. Weickert, and V. J. Carr, “Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis,” Molecular Psychiatry, vol. 16, no. 9, pp. 960–972, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. O. Guillin, C. Demily, and F. Thibaut, “Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine,” International Review of Neurobiology, vol. 78, pp. 377–395, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. J. Chlan-Fourney, P. Ashe, K. Nylen, A. V. Juorio, and X. M. Li, “Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration,” Brain Research, vol. 954, no. 1, pp. 11–20, 2002. View at Publisher · View at Google Scholar · View at Scopus
  107. N. M. Dawson, E. H. Hamid, M. F. Egan, and G. E. Meredith, “Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment,” Synapse, vol. 39, no. 1, pp. 70–81, 2001.
  108. A. M. Lindén, J. Väisänen, M. Lakso, H. Nawa, G. Wong, and E. Castrén, “Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents,” Journal of Molecular Neuroscience, vol. 14, no. 1-2, pp. 27–37, 2000. View at Scopus
  109. V. Parikh, M. M. Khan, and S. P. Mahadik, “Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol,” Neuroscience Letters, vol. 356, no. 2, pp. 135–139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  110. V. Parikh, A. V. Terry, M. M. Khan, and S. P. Mahadik, “Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine,” Psychopharmacology, vol. 172, no. 4, pp. 365–374, 2004. View at Publisher · View at Google Scholar · View at Scopus
  111. A. V. Terry Jr., D. A. Gearhart, S. Warner et al., “Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in rats,” Neuroscience, vol. 150, no. 2, pp. 413–424, 2007. View at Publisher · View at Google Scholar · View at Scopus
  112. A. Pillai and S. P. Mahadik, “Differential effects of haloperidol and olanzapine on levels of vascular endothelial growth factor and angiogenesis in rat hippocampus,” Schizophrenia Research, vol. 87, no. 1–3, pp. 48–59, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. L. Pozzi, K. Håkansson, A. Usiello et al., “Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum,” Journal of Neurochemistry, vol. 86, no. 2, pp. 451–459, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. B. H. Yang, H. Son, S. Hyeon Kim, J. H. Nam, J. H. Choi, and J. S. Lee, “Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration,” Psychiatry and Clinical Neurosciences, vol. 58, no. 3, pp. 262–267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. Z. Freyberg, S. J. Ferrando, and J. A. Javitch, “Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action,” American Journal of Psychiatry, vol. 167, no. 4, pp. 388–396, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. J. J. Crowley, Y. Kim, J. P. Szatkiewicz, A. L. Pratt, C. R. Quackenbush, and D. E. Adkins, “Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice,” Mammalian Genome., vol. 23, no. 5-6, pp. 322–335, 2012.
  117. D. K. Putnam, J. Sun, and Z. Zhao, “Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling,” in Proceedings of the AMIA Annual Symposium, pp. 1127–1133, 2011.
  118. J. Nacher and B. S. McEwen, “The role of N-methyl-D-asparate receptors in neurogenesis,” Hippocampus, vol. 16, no. 3, pp. 267–270, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. T. Archer, R. J. Beninger, T. Palomo, and R. M. Kostrzewa, “Epigenetics and biomarkers in the staging of neuropsychiatric disorders,” Neurotoxicity Research, vol. 18, no. 3-4, pp. 347–366, 2010. View at Publisher · View at Google Scholar · View at Scopus
  120. N. P. Maric and D. M. Svrakic, “Why schizophrenia genetics needs epigenetics: a review,” Psychiatria Danubina, vol. 24, no. 1, pp. 2–18, 2012.
  121. J. Sun, J. Sun, G. L. Ming, and H. Song, “Epigenetic regulation of neurogenesis in the adult mammalian brain,” European Journal of Neuroscience, vol. 33, no. 6, pp. 1087–1093, 2011. View at Publisher · View at Google Scholar · View at Scopus
  122. S. S. Newton and R. S. Duman, “Neurogenic actions of atypical antipsychotic drugs and therapeutic implications,” CNS Drugs, vol. 21, no. 9, pp. 715–725, 2007. View at Publisher · View at Google Scholar · View at Scopus
  123. U. Meyer and J. Feldon, “Epidemiology-driven neurodevelopmental animal models of schizophrenia,” Progress in Neurobiology, vol. 90, no. 3, pp. 285–326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. M. S. Trivedi and T. Jarbe, “A brief review on recent developments in animal models of schizophrenia,” Indian Journal of Pharmacology, vol. 43, no. 4, pp. 375–380, 2011.
  125. M. Yanagi, S. Southcott, J. Lister, and C. A. Tamminga, “Animal models of schizophrenia emphasizing construct validity,” Progress in Molecular Biology and Translational Science, vol. 105, pp. 411–444, 2012.
  126. C. Wilson and A. V. Terry Jr., “Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development,” Clinical Schizophrenia and Related Psychoses, vol. 4, no. 2, pp. 124–137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. J. P. Kesby, D. W. Eyles, T. H. J. Burne, and J. J. McGrath, “The effects of vitamin D on brain development and adult brain function,” Molecular and Cellular Endocrinology, vol. 347, no. 1-2, pp. 121–127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  128. J. J. McGrath, T. H. Burne, F. Féron, A. MacKay-Sim, and D. W. Eyles, “Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update,” Schizophrenia Bulletin, vol. 36, no. 6, pp. 1073–1078, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. J. O'Loan, D. W. Eyles, J. Kesby, P. Ko, J. J. McGrath, and T. H. J. Burne, “Vitamin D deficiency during various stages of pregnancy in the rat; its impact on development and behaviour in adult offspring,” Psychoneuroendocrinology, vol. 32, no. 3, pp. 227–234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. D. Eyles, J. Brown, A. Mackay-Sim, J. McGrath, and F. Feron, “Vitamin D3 and brain development,” Neuroscience, vol. 118, no. 3, pp. 641–653, 2003. View at Publisher · View at Google Scholar · View at Scopus
  131. P. Ko, R. Burkert, J. McGrath, and D. Eyles, “Maternal vitamin D3 deprivation and the regulation of apoptosis and cell cycle during rat brain development,” Developmental Brain Research, vol. 153, no. 1, pp. 61–68, 2004. View at Publisher · View at Google Scholar · View at Scopus
  132. A. Becker, D. W. Eyles, J. J. McGrath, and G. Grecksch, “Transient prenatal vitamin D deficiency is associated with subtle alterations in learning and memory functions in adult rats,” Behavioural Brain Research, vol. 161, no. 2, pp. 306–312, 2005. View at Publisher · View at Google Scholar · View at Scopus
  133. G. Kempermann and F. H. Gage, “Neurogenesis in the adult hippocampus,” in Proceedings of the Novartis Foundation Symposium, vol. 231, pp. 220–235, 2000.
  134. H. Y. Meltzer, S. Park, and R. Kessler, “Cognition, schizophrenia, and the atypical antipsychotic drugs,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 24, pp. 13591–13593, 1999. View at Publisher · View at Google Scholar · View at Scopus
  135. A. L. Mishara and T. E. Goldberg, “A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book,” Biological Psychiatry, vol. 55, no. 10, pp. 1013–1022, 2004. View at Publisher · View at Google Scholar · View at Scopus
  136. A. Becker and G. Grecksch, “Pharmacological treatment to augment hole board habituation in prenatal Vitamin D-deficient rats,” Behavioural Brain Research, vol. 166, no. 1, pp. 177–183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. F. Féron, T. H. J. Burne, J. Brown et al., “Developmental Vitamin D3 deficiency alters the adult rat brain,” Brain Research Bulletin, vol. 65, no. 2, pp. 141–148, 2005. View at Publisher · View at Google Scholar · View at Scopus
  138. G. Keilhoff, “nNOS deficiency-induced cell proliferation depletes the neurogenic reserve,” Neuroscience Letters, vol. 505, no. 3, pp. 248–253, 2011.
  139. S. H. Fatemi, E. S. Emamian, D. Kist et al., “Defective corticogenesis and reduction in Reelin immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice,” Molecular Psychiatry, vol. 4, no. 2, pp. 145–154, 1999. View at Scopus
  140. D. S. Macedo, D. P. Araujo, L. R. Sampaio, S. M. Vasconcelos, P. M. Sales, and F. C. Sousa, “Animal models of prenatal immune challenge and their contribution to the study of schizophrenia: a systematic review,” Brazilian Journal of Medical and Biological Research, vol. 45, no. 3, pp. 179–186, 2012.
  141. K. Cui, H. Ashdown, G. N. Luheshi, and P. Boksa, “Effects of prenatal immune activation on hippocampal neurogenesis in the rat,” Schizophrenia Research, vol. 113, no. 2-3, pp. 288–297, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. F. Lanté, J. Meunier, J. Guiramand et al., “Late N-acetylcysteine treatment prevents the deficits induced in the offspring of dams exposed to an immune stress during gestation,” Hippocampus, vol. 18, no. 6, pp. 602–609, 2008. View at Publisher · View at Google Scholar · View at Scopus
  143. U. Meyer, M. Nyffeler, B. K. Yee, I. Knuesel, and J. Feldon, “Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice,” Brain, Behavior, and Immunity, vol. 22, no. 4, pp. 469–486, 2008. View at Publisher · View at Google Scholar · View at Scopus
  144. S. A. Wolf, A. Melnik, and G. Kempermann, “Physical exercise increases adult neurogenesis and telomerase activity, and improves behavioral deficits in a mouse model of schizophrenia,” Brain, Behavior, and Immunity, vol. 25, no. 5, pp. 971–980, 2011. View at Publisher · View at Google Scholar · View at Scopus
  145. G. Kempermann, J. Krebs, and K. Fabel, “The contribution of failing adult hippocampal neurogenesis to psychiatric disorders,” Current Opinion in Psychiatry, vol. 21, no. 3, pp. 290–295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  146. A. Reif, A. Schmitt, S. Fritzen, and K. P. Lesch, “Neurogenesis and schizophrenia: dividing neurons in a divided mind?” European Archives of Psychiatry and Clinical Neuroscience, vol. 257, no. 5, pp. 290–299, 2007. View at Publisher · View at Google Scholar · View at Scopus
  147. C. T. Toro and J. F. W. Deakin, “Adult neurogenesis and schizophrenia: a window on abnormal early brain development?” Schizophrenia Research, vol. 90, no. 1–3, pp. 1–14, 2007. View at Publisher · View at Google Scholar · View at Scopus
  148. Z. J. Zhang and G. P. Reynolds, “A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia,” Schizophrenia Research, vol. 55, no. 1-2, pp. 1–10, 2002. View at Publisher · View at Google Scholar · View at Scopus
  149. Y. Piontkewitz, M. Arad, and I. Weiner, “Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia,” Schizophrenia Bulletin, vol. 37, no. 6, pp. 1257–1269, 2011.
  150. Y. Piontkewitz, Y. Assaf, and I. Weiner, “Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia,” Biological Psychiatry, vol. 66, no. 11, pp. 1038–1046, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. N. M. Fournier and R. S. Duman, “Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression,” Behavioural Brain Research, vol. 227, no. 2, p. 440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  152. A. Louissaint Jr., S. Rao, C. Leventhal, and S. A. Goldman, “Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain,” Neuron, vol. 34, no. 6, pp. 945–960, 2002. View at Publisher · View at Google Scholar · View at Scopus
  153. A. Schänzer, F. P. Wachs, D. Wilhelm et al., “Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor,” Brain Pathology, vol. 14, no. 3, pp. 237–248, 2004. View at Scopus
  154. N. A. Uranova, I. S. Zimina, O. V. Vikhreva, N. O. Krukov, V. I. Rachmanova, and D. D. Orlovskaya, “Ultrastructural damage of capillaries in the neocortex in schizophrenia,” The World Journal of Biological Psychiatry, vol. 11, no. 3, pp. 567–578, 2010. View at Scopus
  155. D. A. Lewis, T. Hashimoto, and D. W. Volk, “Cortical inhibitory neurons and schizophrenia,” Nature Reviews Neuroscience, vol. 6, no. 4, pp. 312–324, 2005. View at Publisher · View at Google Scholar · View at Scopus
  156. Z. Abdul-Monim, J. C. Neill, and G. P. Reynolds, “Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat,” Journal of Psychopharmacology, vol. 21, no. 2, pp. 198–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  157. S. Berretta, N. Lange, S. Bhattacharyya, R. Sebro, J. Garces, and F. M. Benes, “Long-term effects of amygdala GABA receptor blockade on specific subpopulations of hippocampal interneurons,” Hippocampus, vol. 14, no. 7, pp. 876–894, 2004. View at Publisher · View at Google Scholar · View at Scopus
  158. M. K. Harte, S. B. Powell, N. R. Swerdlow, M. A. Geyer, and G. P. Reynolds, “Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats,” Journal of Neural Transmission, vol. 114, no. 7, pp. 893–898, 2007. View at Publisher · View at Google Scholar · View at Scopus
  159. D. J. Lodge, M. M. Behrens, and A. A. Grace, “A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia,” Journal of Neuroscience, vol. 29, no. 8, pp. 2344–2354, 2009. View at Publisher · View at Google Scholar · View at Scopus
  160. S. Penschuck, P. Flagstad, M. Didriksen, M. Leist, and A. T. Michael-Titus, “Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia,” European Journal of Neuroscience, vol. 23, no. 1, pp. 279–284, 2006. View at Publisher · View at Google Scholar · View at Scopus
  161. M. Makinodan, K. Tatsumi, T. Manabe et al., “Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring,” Journal of Neuroscience Research, vol. 86, no. 10, pp. 2190–2200, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. M. Nyffeler, U. Meyer, B. K. Yee, J. Feldon, and I. Knuesel, “Maternal immune activation during pregnancy increases limbic GABAA receptor immunoreactivity in the adult offspring: implications for schizophrenia,” Neuroscience, vol. 143, no. 1, pp. 51–62, 2006. View at Publisher · View at Google Scholar · View at Scopus
  163. A. Becker, G. Grecksch, H. Schwegler, and T. Roskoden, “Expression of mRNA of neurotrophic factors and their receptors are significantly altered after subchronic ketamine treatment,” Medicinal Chemistry, vol. 4, no. 3, pp. 256–263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  164. A. Becker, B. Peters, H. Schroeder, T. Mann, G. Huether, and G. Grecksch, “Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 27, no. 4, pp. 687–700, 2003. View at Publisher · View at Google Scholar · View at Scopus
  165. C. Ikonomidou, F. Bosch, M. Miksa et al., “Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain,” Science, vol. 283, no. 5398, pp. 70–74, 1999. View at Publisher · View at Google Scholar · View at Scopus
  166. J. W. Olney, J. Labruyere, G. Wang, D. F. Wozniak, M. T. Price, and M. A. Sesma, “NMDA antagonist neurotoxicity: mechanism and prevention,” Science, vol. 254, no. 5037, pp. 1515–1518, 1991. View at Scopus
  167. G. Keilhoff, H. G. Bernstein, A. Becker, G. Grecksch, and G. Wolf, “Increased neurogenesis in a rat ketamine model of schizophrenia,” Biological Psychiatry, vol. 56, no. 5, pp. 317–322, 2004. View at Publisher · View at Google Scholar · View at Scopus
  168. J. E. Malberg and L. M. Monteggia, “VGF, a new player in antidepressant action?” Science Signaling, vol. 1, no. 18, article pe19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  169. J. E. Malberg, A. J. Eisch, E. J. Nestler, and R. S. Duman, “Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus,” Journal of Neuroscience, vol. 20, no. 24, pp. 9104–9110, 2000. View at Scopus
  170. A. Becker, G. Grecksch, H. G. Bernstein, V. Höllt, and B. Bogerts, “Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis,” Psychopharmacology, vol. 144, no. 4, pp. 333–338, 1999. View at Publisher · View at Google Scholar · View at Scopus
  171. E. W. P. M. Daenen, J. A. Van der Heyden, C. G. Kruse, G. Wolterink, and J. M. Van Ree, “Adaptation and habituation to an open field and responses to various stressful events in animals with neonatal lesions in the amygdala or ventral hippocampus,” Brain Research, vol. 918, no. 1-2, pp. 153–165, 2001. View at Publisher · View at Google Scholar · View at Scopus
  172. K. Y. Tseng, R. A. Chambers, and B. K. Lipska, “The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia,” Behavioural Brain Research, vol. 204, no. 2, pp. 295–305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  173. G. K. Wood, B. K. Lipska, and D. R. Weinberger, “Behavioral changes in rats with early ventral hippocampal damage vary with age at damage,” Developmental Brain Research, vol. 101, no. 1-2, pp. 17–25, 1997. View at Publisher · View at Google Scholar · View at Scopus
  174. B. K. Lipska, Z. Z. Khaing, C. S. Weickert, and D. R. Weinberger, “BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs,” European Journal of Neuroscience, vol. 14, no. 1, pp. 135–144, 2001. View at Publisher · View at Google Scholar · View at Scopus
  175. P. C. Ashe, J. Chlan-Fourney, A. V. Juorio, and X. M. Li, “Brain-derived neurotrophic factor (BDNF) mRNA in rats with neonatal ibotenic acid lesions of the ventral hippocampus,” Brain Research, vol. 956, no. 1, pp. 126–135, 2002. View at Publisher · View at Google Scholar · View at Scopus
  176. B. K. Lipska, “Using animal models to test a neurodevelopmental hypothesis of schizophrenia,” Journal of Psychiatry and Neuroscience, vol. 29, no. 4, pp. 282–286, 2004. View at Scopus
  177. H. A. Al-Amin, D. R. Weinberger, and B. K. Lipska, “Exaggerated MK-801-induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus,” Behavioural Pharmacology, vol. 11, no. 3-4, pp. 269–278, 2000. View at Scopus